Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects

Registration

Registration

NCT01967589

Study type

INTERVENTIONAL

Allocation

RANDOMIZED

Phase

PHASE1

Masking

DOUBLE

Status

COMPLETED

Enrollment

82

Start

2013-10

Primary completion

2014-05

Lead sponsor

Novo Nordisk A/S

Conditions

Diabetes; Healthy

Interventions

DRUG:NNC0113-0987; DRUG:placebo

Results posted

FALSE

Secondary identifiers

EUDRACT_NUMBER:2012-002893-30; OTHER:U1111-1131-8724

Registered primary outcomes

• Number of treatment emergent adverse events (TEAEs) recorded [From the time of first dosing (Day 0) and until completion of the post-treatment follow-up visit (Day 83-97)]